American Association for Cancer Research (AACR) Annual Meeting 2023

Orlando, Florida, US 14 April 2023 - 19 April 2023

Pembrolizumab plus gemcitabine/cisplatin improves survival in metastatic biliary tract cancer

30 Jun 2023 by

Treatment with pembrolizumab (pembro) in combination with gemcitabine and cisplatin (gem/cis) results in a statistically significant, clinically meaningful improvement in overall survival (OS) when compared with placebo plus gem/cis in patients with previously untreated metastatic or unresectable biliary tract cancer (BTC), results of the KEYNOTE-966 study have shown.

Pembrolizumab plus gemcitabine/cisplatin improves survival in metastatic biliary tract cancer

30 Jun 2023

Pegargiminase plus chemo improves survival in nonepithelioid pleural mesothelioma

29 Jun 2023 by

Chemotherapy with pemetrexed and cisplatin with ADI-PEG20 (pegargiminase), an arginine-depleting agent, results in better survival and demonstrates a favourable safety profile in patients with nonepithelioid pleural mesothelioma (PM), according to a study presented at AACR 2023.

Pegargiminase plus chemo improves survival in nonepithelioid pleural mesothelioma

29 Jun 2023

Add-on mRNA cancer vaccine delivers promise for melanoma

20 Jun 2023 by

Adding mRNA-4157, an investigational personalized neoantigen cancer vaccine, to the immune checkpoint inhibitor (ICI) pembrolizumab significantly improved recurrence-free survival (RFS) in individuals with resected high-risk melanoma, findings from the phase IIb KEYNOTE 942 study suggest.

Add-on mRNA cancer vaccine delivers promise for melanoma

20 Jun 2023

Perioperative durvalumab-based regimen improves outcomes in resectable NSCLC

12 Jun 2023 by

In individuals with resectable non-small-cell lung cancer (NSCLC), the addition of perioperative durvalumab to neoadjuvant chemotherapy improved pathologic complete response (pCR) and event-free survival (EFS), findings from the AEGEAN study have shown.

Perioperative durvalumab-based regimen improves outcomes in resectable NSCLC

12 Jun 2023